NCT03457948: Pembrolizumab in With Liver-Directed or Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors With Metastases

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: SSTR+ (Somatostatin Receptor
Breast Cancer Tissue: Neuroendocrine tumor (NET)
Recruitment Status: Recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Radiation Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Liver
Additional Notes: Patient must have at least one SSTR+ lesion to be eligible for group 1, or one liver lesion to be eligible for groups 2-4
Exclusions: Patients with leptomeningeal disease or untreated symptomatic brain metastases that require treatment – see trial for details; Patients with prior therapy of an anti-PD-1/L1/L2 agent; Patients with prior peptide receptor radionuclide therapy (group 1 only)

Comments are closed.

Up ↑